We are studying a new treatment combining Lacutamab with GemOx for patients with relapsed or refractory peripheral T-cell lymphoma. The trial aims to evaluate its effectiveness and safety compared to GemOx alone.
We are testing a new imaging method to improve the staging of advanced gastric cancer. This study aims to see if it can reduce the need for invasive procedures while providing accurate diagnostic information.
We are testing the effectiveness and safety of remibrutinib in adults with moderate to severe hidradenitis suppurativa. The study aims to see if it helps reduce symptoms like flare-ups and skin pain compared to a placebo.
We are studying the effects of KO-2806, both alone and with other treatments, in patients with advanced solid tumors. This research aims to find out how well it works in managing their condition.
We are studying the effectiveness of a new higher-concentration permethrin cream for treating scabies in adults and children. The trial aims to see if this treatment works better than the standard cream and how safe it is.
We are studying two RSV vaccines to see how well they work in patients who have received stem cell transplants. The goal is to understand their immune response and effectiveness compared to healthy individuals.
We are testing new oral antibiotics for patients with febrile urinary tract infections caused by resistant bacteria. The goal is to see if these alternatives are as safe as current treatments.
We are studying if specific markers can help identify patients who can safely stop their anti-TNF treatment while in remission. This may help tailor treatment plans for better health outcomes.
We are investigating a new treatment for patients with advanced solid cancers that have the KRASG12C mutation. The study looks at how this treatment works alone and with another medication.
We are testing a new radiopharmaceutical to see how it works in patients with advanced solid tumors. This study aims to understand its effects on the body and how it can help in future treatments.
We are investigating whether the drug Diamyd can help preserve insulin production in adolescents and adults recently diagnosed with type 1 diabetes. The study will also look at the safety of Diamyd compared to a placebo.
We are studying the safety and potential benefits of injecting fat-derived cells for men with recurrent urethral stenosis after surgery. This trial aims to see if this treatment can improve symptoms and reduce the need for further procedures.
We are studying the effects of opioid-free anesthesia compared to traditional opioid-based anesthesia in patients undergoing breast reconstruction surgery. This research aims to find safer pain management options.
We are studying the safety and effectiveness of a new oral medication, emavusertib, for patients with relapsed or refractory primary central nervous system lymphoma. This trial also explores its use alongside another treatment, ibrutinib.
We are studying a new immunotherapy treatment for patients with early-stage colon cancer to see if it can reduce tumors before surgery. The trial also aims to identify biomarkers that may help tailor treatments and improve patient outcomes.
We are exploring a new method for managing antibiotics in patients with Ventilator-Associated Pneumonia in intensive care. This study aims to see if daily assessments can improve survival and reduce complications.
We are studying whether a 7-day antibiotic treatment is as effective as a 14-day treatment for kidney transplant recipients with acute pyelonephritis. This research aims to improve treatment options and patient safety.
We are testing a new immune cell therapy for individuals with refractory lupus nephritis. The goal is to see if it can improve kidney function in patients who have not responded to other treatments.
We are testing a new treatment for children with KCNT1-related Developmental and Epileptic Encephalopathy. The study aims to evaluate its safety and how it may help reduce seizure activity.
We are studying a new cell therapy for children with transfusion-dependent β-thalassemia to see if it can improve their condition and reduce the need for blood transfusions. The trial will also assess the safety of this treatment.